NASDAQ
0.62USD
-0.07 (-9.50%)
We have scored 6 news catalysts on InspireMD, Inc. (NSPR) over the past 12 months. The biggest single-day move next to one of them came Nov 21, 2025, when NSPR closed +13.5%: “InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. Coverage across the window leans positive (average ticker sentiment +0.40). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
28.8M
P/E
—
EPS
—
Beta
0.91
52W range
0.4254-2.17
Day range
0.58–0.67
Open
0.67
Prev close
0.69
Volume
400K
Avg volume
185.8K
Dividend
0.00
IPO
2011-04-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about InspireMD, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NSPR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.